Recce Ltd has released a press release.
Update on meeting with US FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Additional AU$861,590 R&D Tax Incentive Rebate Received
- Recce Half Yearly Report and Appendix 4D
- Data Submission & Further Communication Request with US FDA
- AusIndustry Awards Recce Financial Support
- US FDA Grants Qualified Infectious Disease Product Designati
Later from Recce Pharmaceuticals
- Update on Progress of Broad Spectrum Antibiotic RECCE 327
- Key Australian Patent for Recces Broad-Spectrum Antibiotics
- Change of Registry Address: Automic P/L - Sydney Office
- Recce Successfully Raises $1.8 million via Placement
- USA Patent Granted for Recces Antibiotics
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals